Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2024.Powered by Capital Market - Live News

Net profit of Ajanta Pharma rose 65.82% to Rs 202.72 crore in the quarter ended March 2024 as against Rs 122.25 crore during the previous quarter ended March 2023. Sales rose 19.53% to Rs 1054.08 crore in the quarter ended March 2024 as against Rs 881.84 crore during the previous quarter ended March 2023.For the full year,net profit rose 38.81% to Rs 816.17 crore in the year ended March 2024 as against Rs 587.98 crore during the previous year ended March 2023. Sales rose 12.45% to Rs 4208.71 crore in the year ended March 2024 as against Rs 3742.64 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales1054.08881.84 20 4208.713742.64 12 OPM %26.4016.94 -27.8520.93 - PBDT312.29185.07 69 1249.33876.05 43 PBT278.04152.05 83 1113.93745.25 49 NP202.72122.25 66 816.17587.98 39 Powered by Capital Market - Live News

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 2 May 2024.Powered by Capital Market - Live News

Net profit of Ajanta Pharma rose 56.14% to Rs 210.03 crore in the quarter ended December 2023 as against Rs 134.51 crore during the previous quarter ended December 2022. Sales rose 13.73% to Rs 1105.15 crore in the quarter ended December 2023 as against Rs 971.77 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales1105.15971.77 14 OPM %28.4217.45 - PBDT325.17201.64 61 PBT290.91168.34 73 NP210.03134.51 56 Powered by Capital Market - Live News

Ajanta Pharma announced that the Board of Directors of the Company at its meeting held on 31 January 2024, has recommended a Second Interim dividend of Rs.26 per share (i.e.1300%), subject to the approval of the shareholders.Powered by Capital Market - Live News